Dimensional Fund Advisors LP Sells 437,763 Shares of OraSure Technologies, Inc. $OSUR

Key Points

• Dimensional Fund Advisors reduced its OraSure Technologies stake by 13.4%, selling 437,763 shares and retaining 2.82 million shares worth approximately $8.46 million, or 3.92% of the company.
• Institutional investors own 93.5% of OraSure, while an OraSure director recently purchased 25,000 shares at $2.99 each, increasing his position by 28.26%.
• OSUR opened at $4.05, near its 52-week high of $4.58, but analysts maintain a cautious outlook with a consensus “Reduce” rating and a $3.00 price target.

Dimensional Fund Advisors LP decreased its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 13.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,820,830 shares of the medical instruments supplier's stock after selling 437,763 shares during the quarter. Dimensional Fund Advisors LP owned approximately 3.92% of OraSure Technologies worth $8,462,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Sei Investments Co. increased its position in OraSure Technologies by 16.4% during the 3rd quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier's stock valued at $103,000 after purchasing an additional 4,536 shares during the period. Russell Investments Group Ltd. raised its stake in OraSure Technologies by 13.3% during the fourth quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier's stock worth $106,000 after buying an additional 5,138 shares during the last quarter. Hsbc Holdings PLC raised its stake in OraSure Technologies by 4.6% during the first quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier's stock worth $421,000 after buying an additional 6,218 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in OraSure Technologies by 102.2% in the third quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 7,720 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 8,133 shares during the last quarter. 93.50% of the stock is owned by institutional investors.

OraSure Technologies Stock Performance

OSUR stock opened at $4.05 on Monday. The stock's 50 day simple moving average is $4.16 and its 200 day simple moving average is $3.43. The company has a market cap of $278.84 million, a P/E ratio of -5.87 and a beta of 1.00. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $4.58.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Weiss Ratings raised OraSure Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, June 4th. Wall Street Zen raised OraSure Technologies from a "sell" rating to a "hold" rating in a research note on Monday. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, OraSure Technologies currently has a consensus rating of "Reduce" and a consensus price target of $3.00.

Insider Transactions at OraSure Technologies

In other OraSure Technologies news, Director Steven Kyle Boyd acquired 25,000 shares of the stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $74,750.00. Following the completion of the acquisition, the director owned 113,462 shares in the company, valued at approximately $339,251.38. This represents a 28.26% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.70% of the company's stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source